FIBROGEN INC - COMMON STOCK

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

07 Aug 2023 11:49:30 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

27 Jul 2023 09:18:57 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

26 Jul 2023 08:45:01 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

25 Jul 2023 15:13:02 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

24 Jul 2023 09:07:22 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

21 Jul 2023 08:57:24 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

20 Jul 2023 08:45:40 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

19 Jul 2023 13:13:24 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

28 Jun 2023 08:46:20 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

27 Jun 2023 08:45:10 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

26 Jun 2023 08:45:18 By NetDania Notify

FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

26 Jun 2023 06:04:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

07 Jun 2023 05:55:00 By Nasdaq GlobeNewswire

FibroGen to Present at Jefferies Global Healthcare Conference

06 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

18 May 2023 06:30:00 By Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2023 Financial Results

08 May 2023 15:01:00 By Nasdaq GlobeNewswire

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

08 May 2023 15:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)

05 May 2023 06:30:00 By Nasdaq GlobeNewswire

FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value

01 May 2023 06:00:00 By Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2023 Financial Results

24 Apr 2023 06:00:00 By Nasdaq GlobeNewswire